Sanofi Faces Another Lawsuit over Taxotere
Sanofi-Aventis faces another lawsuit alleging that its chemotherapy drug Taxotere led to permanent hair loss, or alopecia. The suit accuses the drug maker of failing to adequately warn about the risk of irreversible hair loss. The plaintiff is a California woman who was diagnosed with Stage II breast cancer in 2010. She underwent six … [Read more...]
Auvi-Q Epinephrine Auto-injectors Recalled Because of Potentially Inaccurate Dose Delivery
Sanofi US has voluntarily recalled Auvi-Q epinephrine injection devices because the devices may not deliver an accurate dose, which can result in serious health consequences. The recall involves all Auvi-Q devices currently on the market, both the 0.15 mg and 0.3 mg strengths for hospitals, retailers, and consumers. The recall … [Read more...]
Middle-aged Dronedarone Users Have Higher Risk of Hospitalization
New study results reveal that patients age 61 and younger treated with the heart rhythm drug dronedarone (Multaq) have a higher risk for hospitalization than those with treated other anti-arrhythmic drugs. The study, published in Circulation: Cardiovascular Quality and Outcomes, involved nongeriatric atrial fibrillation (Afib) … [Read more...]
Sanofi-Aventis antibiotic linked to liver failure
Sanofi-Aventis Antibiotic Linked To Complications. According to an internal FDA communication first reported in the Wall Street Journal, the FDA has received reports of 12 cases of liver failure, including four deaths, in patients taking the drug. The memo is also reported to express the FDA's concern that these adverse events … [Read more...]
